Test: SARS-CoV-2 IgG Elisa
SARS-CoV-2 IgG antibody is generated as part of the adaptive human immune response to the virus and determination of antibodies in plasma or serum enables the confirmation of SARS-CoV-2 infection in patients with typical symptoms and in suspected cases without symptoms. A positive test result with the AntiSARS-CoV-2 ELISA (IgG) indicates that antibodies to SARS-CoV-2 were detected, and the individual has potentially been exposed to COVID-19. IgG antibodies to SARS-CoV-2 generally do not begin to appear until 7 –10 days after infection.
The enzyme immunoassay (EIA) test provides a sensitive and specific, semi-quantitative assay for the detection of IgG antibodies to SARS-CoV-2. Highly specific viral protein is used to detect the antibodies to SARS-CoV-2 and limit cross-reaction with other similar viruses.